Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation

ACADIA PHARMACEUTICALS INC

U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).
Ruling came in patent litigation against MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.
Protects Acadia's intellectual property for NUPLAZID, used to treat Parkinson's disease psychosis.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.